WilmerHale Represents Underwriters in $230.5M Celldex Therapeutics Offering

WilmerHale Represents Underwriters in $230.5M Celldex Therapeutics Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Drawing on years of experience in the public and private sectors, our lawyers handle a range of litigation involving the federal government, state and foreign governments, and complex regulatory regimes.
Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the public offering of 8,538,750 shares, reflecting the full exercise of the underwriters’ option to purchase 1,113,750 additional shares, of common stock by Celldex Therapeutics, Inc. The offering priced on November 7, 2023 and closed on November 10, 2023. Celldex received approximately $230.5 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses.

The WilmerHale team representing the underwriters included Lisa Firenze, Scott Lunin, Liz Graffeo, and Giancarlos Rodriguez with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel